Analyst Robyn Karnauskas of Deutsche Bank said Gilead Sciences' (Nasdaq: GILD) Atripla recall was not an issue. 39,233 bottles ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE